Orgenesis stock (US68621F1021): Recent clinical trial progress draws investor attention

Orgenesis Inc reported positive data from its CAR-T therapy trials in February 2026, advancing its position in cell and gene therapy manufacturing. The stock has shown volatility amid biotech sector trends.

Orgenesis Inc, a biotech firm focused on cell and gene therapies, shared encouraging interim results from its ongoing CAR-T clinical trials on February 15, 2026, according to company IR as of 02/15/2026. The data indicated improved patient response rates in relapsed lymphoma cases, boosting interest among US investors tracking innovative treatments.

The stock traded at $1.25 USD on Nasdaq on May 14, 2026, reflecting a 2.1% gain over the prior week amid broader biotech momentum, per Yahoo Finance as of 05/14/2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Orgenesis Inc
• Sector/industry: Biotechnology / Cell & Gene Therapy
• Headquarters/country: Israel / United States
• Core markets: US, Europe, Asia
• Key revenue drivers: CDMO services, clinical trials
• Home exchange/listing venue: Nasdaq (ORGS)
• Trading currency: USD

Orgenesis: core business model

Orgenesis develops and manufactures cell and gene therapies through its Contract Development and Manufacturing Organization (CDMO) platform. The company provides end-to-end solutions from process development to commercial-scale production, targeting therapies for cancer and degenerative diseases. This model positions Orgenesis as a key enabler for biotech innovators lacking in-house manufacturing capabilities.

Founded in 2016 and listed on Nasdaq under ticker ORGS, Orgenesis operates labs in Israel, the US, and Europe. Its proprietary Orgenesis One platform streamlines autologous cell therapies, reducing costs and timelines for partners, as detailed in the company's 2025 annual report published March 28, 2026, via IR filings as of 03/28/2026.

Main revenue and product drivers for Orgenesis

Revenue primarily stems from CDMO services, including tech transfer, process optimization, and GMP manufacturing. In Q4 2025 (reported February 2026), CDMO revenue grew 45% year-over-year to $8.2 million, driven by expanded contracts with US-based partners, according to the earnings release on IR as of 02/15/2026.

Key products include CAR-T therapies like OMG-102 and OMG-301, currently in Phase I/II trials. Partnerships with academic institutions and pharma firms contribute milestone payments and royalties, supporting scalability for US investors eyeing biotech growth.

Industry trends and competitive position

The cell and gene therapy market is projected to reach $45 billion by 2028, per Grand View Research as of 01/2026, fueled by FDA approvals for personalized medicines. Orgenesis competes with Lonza and WuXi AppTec but differentiates via its decentralized manufacturing model, appealing to US firms navigating supply chain challenges.

Why Orgenesis matters for US investors

With Nasdaq listing and significant US revenue exposure (over 50% from North American clients in 2025), Orgenesis offers retail investors access to high-growth biotech without direct R&D risk. Its role in US FDA-regulated trials enhances relevance amid domestic demand for advanced therapies.

Conclusion

Orgenesis continues advancing its CDMO platform amid promising trial data and revenue growth. While biotech stocks carry inherent volatility, the company's strategic focus on scalable manufacturing supports its role in the expanding cell therapy sector. US investors may monitor upcoming trial readouts and partnerships for further developments.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.